Total Payments
$7,998
2024 Payments
$829.99
Companies
21
Transactions
334
Medicare Patients
18,458
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$6,653 (83.2%)
Travel$1,296 (16.2%)
Education$48.62 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,653 | 324 | 83.2% |
| Travel and Lodging | $1,296 | 2 | 16.2% |
| Education | $48.62 | 8 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $1,811 | 12 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,501 | 69 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,411 | 76 | $0 (2024) |
| PFIZER INC. | $728.27 | 44 | $0 (2024) |
| Merck Sharp & Dohme LLC | $489.07 | 21 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $443.42 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $428.76 | 23 | $0 (2024) |
| Amgen Inc. | $305.50 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $296.52 | 20 | $0 (2024) |
| Edwards Lifesciences Corporation | $120.96 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $829.99 | 42 | Novartis Pharmaceuticals Corporation ($205.68) |
| 2023 | $1,203 | 53 | PFIZER INC. ($297.51) |
| 2022 | $1,027 | 61 | Janssen Pharmaceuticals, Inc ($390.97) |
| 2021 | $679.58 | 45 | Janssen Pharmaceuticals, Inc ($223.66) |
| 2020 | $399.72 | 21 | Janssen Pharmaceuticals, Inc ($133.57) |
| 2019 | $837.40 | 34 | Novartis Pharmaceuticals Corporation ($310.73) |
| 2018 | $643.09 | 32 | Novartis Pharmaceuticals Corporation ($238.13) |
| 2017 | $2,379 | 46 | BOSTON SCIENTIFIC CORPORATION ($1,676) |
All Payment Transactions
334 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/05/2024 | PFIZER INC. | VYNDAMAX (Drug) | Education | In-kind items and services | $19.56 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/05/2024 | PFIZER INC. | VYNDAMAX (Drug) | Education | In-kind items and services | $3.20 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $20.56 | General |
| Category: Cardiovascular | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/19/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: DIABETES | ||||||
| 09/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/01/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/25/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $25.71 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $27.99 | General |
| Category: Cardiovascular | ||||||
| 06/27/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/20/2024 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: DIABETES | ||||||
| 05/30/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/09/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 3,829 | 6,445 | $1.1M | $481,523 |
| 2022 | 19 | 3,701 | 6,199 | $1.1M | $485,679 |
| 2021 | 24 | 5,410 | 8,370 | $1.2M | $532,492 |
| 2020 | 32 | 5,518 | 8,496 | $1.2M | $530,154 |
Total Patients
18,458
Total Services
29,510
Medicare Billing
$2.0M
Procedure Codes
100
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 707 | 1,212 | $246,036 | $151,146 | 61.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 228 | 230 | $276,000 | $79,407 | 28.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 422 | 451 | $197,087 | $65,746 | 33.4% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 72 | 74 | $105,080 | $49,501 | 47.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 248 | 277 | $41,827 | $23,240 | 55.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 166 | 668 | $30,816 | $22,753 | 73.8% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 223 | 232 | $24,750 | $19,275 | 77.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 868 | 1,831 | $62,254 | $19,142 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 73 | 73 | $21,170 | $11,919 | 56.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 234 | 237 | $41,375 | $11,600 | 28.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 171 | 253 | $10,120 | $4,337 | 42.9% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 75 | 197 | $13,790 | $3,491 | 25.3% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 63 | 63 | $16,905 | $3,153 | 18.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 48 | 128 | $10,240 | $2,993 | 29.2% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 51 | 56 | $6,039 | $2,988 | 49.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $4,830 | $2,371 | 49.1% |
| 93283 | Programming of dual lead implantable defibrillator system | Office | 2023 | 26 | 28 | $3,966 | $1,971 | 49.7% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 27 | 69 | $7,442 | $1,931 | 25.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 22 | 228 | $9,120 | $1,891 | 20.7% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 73 | 75 | $4,500 | $1,399 | 31.1% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 11 | 42 | $2,120 | $1,270 | 59.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 670 | 1,123 | $228,143 | $148,692 | 65.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 235 | 235 | $282,000 | $86,467 | 30.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 375 | 407 | $177,859 | $61,402 | 34.5% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2022 | 52 | 52 | $73,840 | $38,202 | 51.7% |
About Dr. Christopher Bowens, M.D
Dr. Christopher Bowens, M.D is a Cardiovascular Disease healthcare provider based in Newark, Delaware. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1487657102.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Bowens, M.D has received a total of $7,998 in payments from pharmaceutical and medical device companies, with $829.99 received in 2024. These payments were reported across 334 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($6,653).
As a Medicare-enrolled provider, Bowens has provided services to 18,458 Medicare beneficiaries, totaling 29,510 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Newark, DE
- Active Since 05/27/2005
- Last Updated 10/17/2017
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1487657102
Products in Payments
- WATCHMAN (Device) $1,760
- XARELTO (Drug) $1,501
- ENTRESTO (Drug) $1,193
- ELIQUIS (Drug) $501.50
- VERQUVO (Drug) $489.07
- BRILINTA (Drug) $408.99
- JARDIANCE (Drug) $398.62
- VYNDAQEL (Drug) $372.76
- LEQVIO (Drug) $217.61
- Corlanor (Drug) $168.67
- Repatha (Biological) $136.83
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $120.96
- PRALUENT (Drug) $90.30
- CAMZYOS (Drug) $83.69
- LifeVest (Device) $72.32
- Vascepa (Drug) $44.49
- VYNDAMAX (Drug) $40.86
- Arcalyst (Drug) $35.35
- MULTAQ (Drug) $30.46
- Cardiac Monitor (Device) $29.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Newark
Michael Stillabower, M.d, M.D
Cardiovascular Disease — Payments: $219,666
Cardiovascular Disease $219,666
Muhamed Saric, M.d, M.D
Cardiovascular Disease — Payments: $204,438
Cardiovascular Disease $204,438
Mr. Edward Goldenberg, M.d, M.D
Cardiovascular Disease — Payments: $134,686
Cardiovascular Disease $134,686
Dr. William Weintraub, Md, MD
Cardiovascular Disease — Payments: $51,776
Cardiovascular Disease $51,776
Dr. Anthony Alfieri, D.o, D.O
Cardiovascular Disease — Payments: $46,946
Cardiovascular Disease $46,946
Firas Qaqa, M.d, M.D
Cardiovascular Disease — Payments: $44,682
Cardiovascular Disease $44,682